The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s Vaxxinity and the Phase II clinical trials completion for a Taiwanese COVID treatment.
Bora consolidates its position in Taiwan’s CDMO sector (BioSpectrum Asia Edition)
To consolidate its position on the CDMO market, Taiwan-based Bora Pharmaceuticals recently created Bora Biologics Co., Ltd., a CDMO platform for biologics. In addition, Bora has also announced that they will initially invest $50 million and up to $100 million in the acquisition of Eden Biologics’ CDMO assets in Taiwan.
The company has established itself as a leading CDMO for small molecules and biological macromolecules and the strategic acquisition of Eden Biologics CDMO assets will help Bora Group to build a presence in the biological macromolecules and cell and gene therapy markets, and expand its service offering to support new and innovative drug development.
FDA Fast Track for United Biomedical’s US-based spinoff Vaxxinity’s Alzheimer’s Vaccine (Taiwan Life Sciences Newsletter)
The Taiwanese biomedical group United Biomedical’s US-based spinoff, Vaxxinity, announced that its therapeutic vaccine for Alzheimer’s disease (UB-311) has been approved by the US Food and Drug Administration (FDA) for Fast Track Designation (FTD).
Fast Track Designation (FTD) is designed to facilitate the development and expedited review of new drugs to treat serious or life-threatening diseases to address unmet medical needs and provide patients with early access to effective new drug treatments.
HCmed medical nebulizer approved in Australia (Taiwan Life Sciences Newsletter)
Taiwan-headquartered inhaled drug medical devices company HCmed Innovations’ Pulmogine, a new mesh nebulizer, has obtained medical device approval from the Australian Therapeutic Goods Administration (TGA).
According to HCmed, the global inhaled drug market will exceed US$41 billion in 2026 and because of COVID-19-related pneumonia in the past two years, the demand for inhaled lung treatment therapies has increased.
Taiwanese COVID treatment has completed Phase II clinical trials (Taiwan Life Sciences Newsletter)
Taiwanese drug development company Foresee Pharmaceuticals’ Phase II clinical trial for an MMP-12 inhibitor FP-025 in the treatment of critically ill COVID-19 patients was completed, with data expected to be released in the second half of this year.
According to the company, with the recent decline in severe COVID-19 patients, its new drug will be mainly used to treat acute respiratory distress syndrome (ARDS), one of the main causes of death in COVID-19 patients in critically ill COVID-19 patients.
Adimmune, TTY Biopharm, Sanofi win bids for Taiwan’s flu vaccine (Taiwan Life Sciences Newsletter)
Taiwan’s Center for Disease Control (CDC) under the Ministry of Health and Welfare announced the results for this years’ public-funded influenza vaccine. Adimmune won the bid for 3.275 million doses, which accounts for more than half of the total procurement volume, with a total amount of more than NTD780 million. Taiwan’s TTY Biopharm was awarded the bid for 1.13 million doses, with Sanofi S.A. winning the third the bid.
Japan’s Rohto Pharmaceutical Co., Ltd new partner for Taiwan mobile health company, iXensor (Taiwan Life Sciences Newsletter)
Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder in iXensor, a Taiwanese mobile health business. iXensor received Rohto Pharmaceutical’s strategic investment to expand its mobile health business globally and accelerate its PixoTech platform licensing business.
